RVMD CFO sells 20K shares, exercises options
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported a combination of stock sales and an option exercise in company shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported a combination of stock sales and an option exercise in company shares. On June 24, 2026, he sold 20,000 shares of common stock in multiple open-market transactions at prices generally around $167–$170 per share, executed under a Rule 10b5-1 trading plan adopted on March 24, 2026. On the same date, he exercised stock options to acquire 20,000 shares of common stock at an exercise price of $18.56 per share. After these transactions, he directly owns 123,269 shares of Revolution Medicines common stock, which includes 51,388 restricted stock units.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,000 shares ($3.00M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Anders Jack
Role
Chief Financial Officer
Sold
20,000 shs ($3.37M)
Approx. gross sale proceeds
$3.37M
Approx. exercise cost
$371K
Approx. pre-tax spread
$3.00M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 20,000 | $18.56 | $371K |
| Sale | Common Stock | 4,553 | $167.345 | $762K |
| Sale | Common Stock | 9,496 | $168.1959 | $1.60M |
| Sale | Common Stock | 5,651 | $169.2441 | $956K |
| Sale | Common Stock | 300 | $170.32 | $51K |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,600 contracts (Direct);
Common Stock — 123,269 shares (Direct)
Footnotes (6)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026.
- F2. Includes 51,388 restricted stock units.
- F3. This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 20,000 shares
Shares acquired via option exercise: 20,000 shares
Option exercise price: $18.56 per share
+4 more
7 metrics
Shares sold
20,000 shares
Open-market sales of common stock on June 24, 2026
Shares acquired via option exercise
20,000 shares
Stock option exercise to buy common stock on June 24, 2026
Option exercise price
$18.56 per share
Strike price for Stock Option (Right to Buy)
Post-transaction holdings
123,269 shares
Common stock directly owned after reported transactions
Restricted stock units included
51,388 RSUs
Portion of reported 123,269 shares classified as RSUs
Example sale price
$170.32 per share
Weighted average price for a 300-share sale tranche
Sale price range
$166.76–$170.60
Price ranges for multiple trade executions on June 24, 2026
Key Terms
Rule 10b5-1 trading plan, restricted stock units, open-market sale, Stock Option (Right to Buy), +1 more
5 terms
Rule 10b5-1 trading plan financial
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 51,388 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did RVMD CFO Anders Jack report on June 24, 2026?
RVMD CFO Anders Jack reported selling 20,000 shares of common stock and exercising options for 20,000 shares. All transactions occurred on June 24, 2026 and involved open-market sales and a stock option exercise in Revolution Medicines shares.
What options did the RVMD CFO exercise in this Form 4 filing?
The CFO exercised stock options for 20,000 shares of Revolution Medicines common stock at an exercise price of $18.56 per share. These options are described as a Stock Option (Right to Buy) with a stated conversion or exercise price of $18.56.
Were the RVMD CFO’s June 24, 2026 stock sales under a 10b5-1 plan?
Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2026. Such plans pre-schedule trades and are commonly used for routine portfolio management.
What does the Form 4 say about the RVMD CFO’s restricted stock units?
The filing notes that the CFO’s reported ownership includes 51,388 restricted stock units. Restricted stock units typically represent rights to receive shares in the future, subject to vesting conditions set by the company’s equity compensation plans.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates